ADIPOGENIX, INC.

Company Information

Company Name
ADIPOGENIX, INC.
Address
ADIPOGENIX, INC.
801 ALBANY ST, S112
BOSTON, MA, 02119 0251
Phone
1 617-638-6389
URL
n/a
DUNS
n/a
Number of Employees
n/a

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$499,560.00
6
SBIR Phase II
$1,325,815.00
2
Chart code to be here

Award List

  1. ENHANCED DIFFERENTIATION OF HUMAN PREADIPOCYTES

    Amount: $99,972.00

    Not Available The objective of Phase I is to develop and demonstrate a neural networks system to predict, map, and interpolate rotorcraft ground noise exposure data. It is well-known that the relat ...

    SBIR Phase I 1999 Department of Health and Human Services
  2. N/A

    Amount: $99,930.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  3. Anti-obesity drug development using human preadipocytes

    Amount: $0.00

    N/A

    SBIR Phase I 2001 Department of Health and Human Services
  4. Anti-obesity drug development using human preadipocytes

    Amount: $602,471.00

    N/A

    SBIR Phase II 2001 Department of Health and Human Services
  5. SECRETED PROTEIN FROM ADIPOCYTES AND PREADIPOCYTES

    Amount: $99,820.00

    DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. While weight loss is the most effective t ...

    SBIR Phase I 2002 Department of Health and Human Services
  6. New Agents That Inhibit Fatty Acid Accumulation

    Amount: $99,894.00

    DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Although weight loss is the most effectiv ...

    SBIR Phase I 2003 Department of Health and Human Services
  7. Activators of Adipocyte Fatty Acid Oxidation

    Amount: $99,944.00

    DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Existing drug and dietary treatments for ...

    SBIR Phase I 2003 Department of Health and Human Services
  8. New Agents That Inhibit Fatty Acid Accumulation

    Amount: $723,344.00

    DESCRIPTION (provided by applicant): Obesity is a well-established risk factor for a number of diseases, including type 2 diabetes and coronary heart disease. Existing treatments for obesity are only ...

    SBIR Phase II 2004 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government